Visual Abstracts
#VisualAbstract: Administering bortezomib on a weekly basis VS twice weekly basis does not significantly affect progression-free survival (PFS) or overall survival (OS) in Vrd first-line therapy for multiple myeloma
See what other members have to say:
"Very useful, I have filled many gaps and gained practical knowledge."
"I feel now more confident in diagnosing the presented conditions. Really it is one of the best learning activities I have completed recently."